Urol. praxi, 2016; 17(1): 23-26 | DOI: 10.36290/uro.2016.006

Testosteron replacement therapy and cardiovascular risk

MUDr.Aleš Horák
ANDROPHARM medical s.r.o., Urologicko-andrologická ambulance, Ostrava

During the last years increase number of hypogonadal men with testosteron replacement therapy (TRT). Continually is assesed

benefit this therapy with possible risk including cardiovascular diseases (CVD). In conformity with actually findings is not increase

CVD risk by TRT.

Keywords: hypogonadal men, testosteron replacement therapy, cardiovascular diseases

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák A. Testosteron replacement therapy and cardiovascular risk. Urol. praxi. 2016;17(1):23-26. doi: 10.36290/uro.2016.006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome, Nature Reviews Endocrinology. 2009; 5: 673-681. Go to original source... Go to PubMed...
    2. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JCh, Philip W, James T, Loria CM, Smith SC Jr. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation.2009; 120: 1640-1645. Go to original source... Go to PubMed...
    3. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G. Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes; Diabetes Care.2011; 34(7): 1669-1675. Go to original source... Go to PubMed...
    4. Svartberg J, Mühlen D, Sundsfjord J, Jorde R. Waist Circumference and Testosterone Levels in Community Dwelling Men. The Tromso Study. 2004; 19(7): 657-663. Go to original source...
    5. Shores MM, Matsumoto AM, Sloan KL,Kivlahan DR. Low Serum Testosterone and Mortality in Male Veterans, Arch Intern Med. 2006; 166(15): 1660-1665. Go to original source... Go to PubMed...
    6. Haider A, Gooren LJ, Padungtod P, et al. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes. 2010; 118(3): 167-171. Go to original source... Go to PubMed...
    7. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010; 95(2): 639-650. Go to original source... Go to PubMed...
    8. Rao P, Brooke JC, Walter D, et al. Testosterone replacement therapy has beneficial effects on cardiovascular risk factors and liver function in hypogonadal men. Endocrine Rev. 2013; 34(3 Meeting Abstracts): SAT-573.
    9. Corona G, Maseroli E, Rastrelli G, Isidori A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone boosting medications: a systematic review and metaanalysis. Exp Opin Drug Safety 2014; Posted online on August 19, 2014. Go to original source... Go to PubMed...
    10. Sharma R, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Dostupný z http://dx.doi.org/10.1093/eurheartj/ehv3462706-2715. [cit. 2015-15-11]
    11. Morgentaler A. Testosterone Therapy and Cardiovascular Risks. Dostupný z http://www.prismhealthonline.com/lms/mod/page/view.php?id=196. [cit. 2015-20-11]
    12. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. New Engl J Med. 2010; 363(2): 109-122. Go to original source... Go to PubMed...
    13. Finkle WD, Greenland S, RidgewayGK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS One, 2014; 9(1). Go to original source...
    14. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013; 310(17): 1829-1836. Go to original source... Go to PubMed...
    15. Nejednoznačné důkazy o zvýšeném riziku srdečních problémů u léčivých přípravků obsahujících testosteron. Dostupný z http://www.ema.europa.eu/docs/cs_CZ/document_library/Referrals_document/Testosterone_31/Position_provided_by_CMDh/WC500177617.pdf. [cit. 2015-20-11]
    16. Testosterone Replacement Therapy Advisory Committee Briefing Document, Dostupný z http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm412537.pdf. [cit. 2015-20-11]
    17. Testosteron - zvýšené kardiovaskulární riziko není potvrzeno. Dostupný z http://www.sukl.cz/testosteron-zvysene-kardiovaskularni-riziko-neni-potvrzeno?highlightWords=testosteron. [cit. 2015-20-11]
    18. Testosteron - Výbor PRAC nepotvrdil zvýšené riziko kardiovaskulárních nežádoucích účinků. Dostupný z http://www.sukl.cz/testosteron-vybor-prac-nepotvrdil-zvysene-riziko. [cit. 2015-20-11]
    19. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. Guidelines on Male Hypogonadism. Dostupný z http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-Hypogonadism-2015.pdf. [cit. 2015-20-11]

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.